This Biomedical Company Announces Major Tick-Borne Disease Study
60 Degrees Pharma Moves Forward with Tafenoquine Study for Tick-Borne Disease, Babesiosis.
Please note: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
60 Degrees Pharmaceuticals (60P), a bio-pharmaceutical company committed to developing innovative solutions for neglected and under-treated diseases, recently announced its Institutional Review Board (IRB) approval for a Phase IIA study. The study aims to evaluate the effectiveness of Tafenoquine in treating Babesiosis, an emerging tick-borne disease. Furthermore, the company has rescheduled its Type C meeting with the Food and Drug Administration (FDA) to January 17, 2024.
60 Degrees Pharmaceuticals, headquartered in Washington D.C., has been working diligently to develop a solution to combat this rising health concern. The company's focus on neglected and under-treated diseases has led them to Tafenoquine, a medication initially approved by the FDA in 2018 for the prevention of malaria.
The IRB approval marks a significant milestone for 60P as it allows the company to move forward with its Phase IIA study. This study will assess the safety, tolerability, and effectiveness of Tafenoquine in patients diagnosed with Babesiosis. The ultimate goal is to provide a new treatment alternative that could potentially save lives and improve the quality of life for those affected by this debilitating disease.
The upcoming Type C meeting with the FDA will provide 60P with the opportunity to discuss important aspects of the study design, endpoints, and statistical considerations. The meeting was initially scheduled for late 2023 but has been postponed to January 17, 2024, as announced by 60P.
While this news from 60 Degrees Pharmaceuticals represents a significant step forward in the fight against Babesiosis, it also serves as a reminder of the ongoing challenges faced by those living in tick-prone areas. As we await further developments, it's crucial to take preventive measures against tick bites and to be aware of the symptoms of Babesiosis, which include fever, fatigue, and anemia.
The progress made by 60P is part of a larger trend towards innovative solutions for neglected diseases. It highlights the importance of research and development in the pharmaceutical industry and the potential impact on public health.
As we look forward to the outcomes of the Phase IIA study and the FDA meeting, there is hope that Tafenoquine could become a game-changer in the treatment of Babesiosis and potentially other tick-borne diseases.
Disclaimer: This article contains affiliate links. The author may earn a commission if you make a purchase through these links. This does not influence the content of the article.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources:
2. BioSpace